BLOG

Japan’s Stem Cell Regulations: A Guide for Global Patients

7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

For international patients exploring the potential of regenerative medicine, understanding the regulatory landscape of each country is a critical first step. Stem cell therapies, particularly those using adipose-derived stem cells, are offered under different legal frameworks globally. This article provides an objective overview of how Japan regulates these treatments, comparing its system to those in the United States and Europe, to help you make a more informed decision.

The key takeaway is that Japan’s approach is not about being more or less strict, but fundamentally different. It prioritizes a balance between patient safety and timely access to innovative treatments under the direct supervision of physicians and government oversight.

A Distinct Path: Japan’s Approach to Regenerative Medicine

In 2014, Japan enacted the Act on the Safety of Regenerative Medicine (ASRM). This law established a unique framework for providing cell therapies. Instead of treating all stem cell applications as pharmaceutical drugs that require years of large-scale clinical trials for approval, the ASRM classifies treatments based on their risk level. Medical institutions can provide therapies like autologous (using one’s own cells) adipose-derived stem cell therapy after their treatment plan is reviewed by a certified committee and officially filed with the Ministry of Health, Labour and Welfare (MHLW).

This system treats regenerative medicine as a medical practice conducted under a physician’s responsibility, rather than a mass-produced product. It allows for controlled, case-by-case application while mandating strict standards for cell processing, patient safety management, and data reporting.

How Japan’s Framework Compares to the US and Europe

The primary difference lies in classification and oversight. In the United States, the Food and Drug Administration (FDA) generally regulates stem cell products as drugs if the cells are more than minimally manipulated. This pathway requires a lengthy and costly series of clinical trials (Phase I, II, and III) to prove safety and efficacy before the treatment can be marketed. The European Medicines Agency (EMA) follows a similar path for what it calls Advanced Therapy Medicinal Products (ATMPs).

Japan’s ASRM, by contrast, creates a pathway for earlier clinical access within a regulated environment. The focus is on ensuring the safety of the specific procedure at a specific clinic. This does not mean one system is superior, but that they operate on different principles: the Western model is product-centric and approval-based, while the Japanese model is practice-centric and notification-based, with built-in safety checks.

Safety and Oversight for Adipose Stem Cell Therapy in Japan

Patient safety is the cornerstone of the ASRM. For adipose-derived stem cell therapy provided under this act, the process is rigorously controlled:

  • Independent Review: Before a clinic can offer treatment, its entire plan—from cell collection and processing to administration and patient follow-up—must be scrutinized and approved by a government-certified independent committee of experts.
  • Government Notification: Once approved by the committee, the plan is submitted to the MHLW. This ensures transparency and central oversight.
  • Certified Cell Processing: The facility where stem cells are cultured must comply with strict national standards for safety, quality, and hygiene, similar to a pharmaceutical manufacturing plant.

Because autologous adipose-derived stem cell therapy uses a patient’s own cells, the risk of rejection or allergic reactions is considered lower than with donor cells. However, it is important to remember that all medical procedures carry inherent risks, which must be discussed in detail with a physician during a consultation.

What International Patients Should Know

Japan’s regulatory environment has made it a notable destination for medical tourism in regenerative medicine. If you are considering this option, it is vital to proceed with caution and clarity. This therapy is not a guaranteed cure for any disease or condition and should not be seen as a replacement for standard, evidence-based treatments for serious illnesses.

Crucially, this treatment is provided as private medical care (out-of-pocket) and is not covered by Japanese public health insurance. All costs, the number of sessions, treatment duration, potential risks, and side effects must be thoroughly understood before making a commitment. A comprehensive consultation with a physician is essential to determine if you are a suitable candidate based on your health status and medical history.

Adipose Stem Cell Therapy at Our Clinic in Osaka

At Grand Green Osaka Umekita Clinic, we provide autologous adipose-derived stem cell therapy in strict compliance with the Act on the Safety of Regenerative Medicine. Our treatment plan has been reviewed, approved, and officially filed with the MHLW. We are committed to providing clear, objective information to help patients understand the treatment within the context of Japanese law.

We believe an informed patient is an empowered patient. If you are interested in learning more about the specifics of this therapy, including the process, features, fees, and potential risks and side effects that require careful consideration, we invite you to review our detailed information page. It is available in multiple languages to support our international visitors.

Learn more about Adipose-Derived Stem Cell Therapy

Conclusion: An Informed Decision is Key

Japan’s regulatory framework for stem cell therapy offers a structured, safety-focused alternative to the models found in the US and Europe. For international patients, understanding these differences is the first step toward evaluating if treatment in Japan is a suitable option. The final decision must always be a personal one, made after a thorough medical evaluation and a detailed discussion with a qualified physician who can assess your individual circumstances. The goal is not to seek a miracle cure, but to explore a medically supervised option for supporting your long-term health and well-being.

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Hidenori Shimada

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›

Grand Green Osaka South Building, Gate Tower 5F 5-54 Ofuka-cho, Kita-ku, Osaka 530-0011, Japan

TEL: 06-7653-8493 FAX: 06-7635-8052

Contact